These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 25305789)

  • 21. Word of wisdom. Re: prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review.
    Fransen van de Putte EE; van Rhijn BW
    Eur Urol; 2014 Oct; 66(4):787-8. PubMed ID: 25218075
    [No Abstract]   [Full Text] [Related]  

  • 22. Blood group antigens in transitional cell tumours of the urinary bladder. An immunohistochemical study.
    Juhl BR
    Dan Med Bull; 1994 Feb; 41(1):1-11. PubMed ID: 8187557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CA19.9 and CEA in transitional cell carcinoma of the bladder: serological and immunohistochemical findings.
    Hegele A; Mecklenburg V; Varga Z; Olbert P; Hofmann R; Barth P
    Anticancer Res; 2010 Dec; 30(12):5195-200. PubMed ID: 21187512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ABH secretor status in patients with bladder tumours.
    Paterson PJ
    Urol Res; 1976; 4(4):147-50. PubMed ID: 1020066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antigenic detection and prognosis of patients with transitional cell carcinoma of the urinary bladder.
    Tan LB; Lin LM; Huang CH; Chiang CP; Chien CH; Pan CC
    Urol Int; 1989; 44(5):264-71. PubMed ID: 2800062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploration of the correlations between interferon-γ in patient serum and HEPACAM in bladder transitional cell carcinoma, and the interferon-γ mechanism inhibiting BIU-87 proliferation.
    Xu B; He Y; Wu X; Luo C; Liu A; Zhang J
    J Urol; 2012 Oct; 188(4):1346-53. PubMed ID: 22906662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer.
    Rink M; Chun FK; Minner S; Friedrich M; Mauermann O; Heinzer H; Huland H; Fisch M; Pantel K; Riethdorf S
    BJU Int; 2011 May; 107(10):1668-75. PubMed ID: 20735381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood group isoantigen deletion and chromosomal abnormalities in bladder cancer.
    Pauwels RP; Schapers RF; Smeets AW; Jansen LE; Debruyne FM; Geraedts JP
    J Urol; 1988 Nov; 140(5):959-63. PubMed ID: 3050155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relation between basement membrane degradation and serum levels of laminin P1 in patients with transitional cell carcinoma of the bladder.
    Abou Farha KM; Menheere PP; Nieman FH; Janknegt RA; Arends JW
    Urol Int; 1993; 50(1):13-6. PubMed ID: 8434420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunologic indices of patients with transitional cell carcinoma of the urinary bladder].
    Bkhatta AD; Makhlin NV
    Urol Nefrol (Mosk); 1984; (2):67-70. PubMed ID: 6372193
    [No Abstract]   [Full Text] [Related]  

  • 31. Oestrogen receptor investigations in bladder tumours.
    Kvist E; Albrectsen J
    Scand J Urol Nephrol; 1994 Dec; 28(4):369-70. PubMed ID: 7886413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of CA 125 in transitional cell carcinoma of the bladder.
    Manvar AM; Wallen EM; Pruthi RS; Nielsen ME
    Expert Rev Anticancer Ther; 2010 Dec; 10(12):1877-81. PubMed ID: 21110754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy.
    Engel O; Soave A; Peine S; Kluth LA; Schmid M; Shariat SF; Dahlem R; Fisch M; Rink M
    World J Urol; 2015 Nov; 33(11):1769-76. PubMed ID: 25782867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunofluorescence study of the distribution of ABH cell surface antigens in bladder tumours (author's transl)].
    Vallancien G; Rouger P; Leclerc JP; Kuss R
    Sem Hop; 1982 May; 58(19):1161-4. PubMed ID: 6285497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prognostic value of the detection of ABO surface antigens by indirect immunofluorescence technic in transitional tumors of the bladder].
    Borella T; Loro M; Dato I; Merlo F; Giudici M
    Minerva Med; 1986 Sep; 77(34-35):1527-32. PubMed ID: 3531921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A,B blood group antigens in tissues of AB heterozygotes. Emphasis on normal and neoplastic urothelium.
    Limas C
    Am J Pathol; 1990 Nov; 137(5):1157-62. PubMed ID: 2240163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison between tissue antigen analysis and plasma determinations for TPA and CEA in transitional cell carcinomas and in tumorfree urothelium of the urinary bladder.
    Vogel J; Oehr P; Maisey R; Adolphs HD
    Cancer Detect Prev; 1988; 11(3-6):389-96. PubMed ID: 2455597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The importance of transurethral resection of bladder tumor in the management of nonmuscle invasive bladder cancer: a systematic review of novel technologies.
    Richards KA; Smith ND; Steinberg GD
    J Urol; 2014 Jun; 191(6):1655-64. PubMed ID: 24518761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blood group ABO and Lewis antigens in bladder tumors: correlation between glycosyltransferase activity and antigen expression.
    Orntoft TF; Wolf H
    APMIS Suppl; 1988; 4():126-33. PubMed ID: 3146987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential value of soluble intercellular adhesion molecule-1 in the serum of patients with bladder cancer.
    Ozer G; Altinel M; Kocak B; Balci M; Altan A; Gonenc F
    Urol Int; 2003; 70(3):167-71. PubMed ID: 12660451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.